ArticleHealth science reports2025
Prevalence and Genotype Distribution of Human Papillomavirus Among Males in Shantou, China (2019-2023).
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Human papillomavirus (HPV) is one of the most prevalent sexually transmitted infections globally, posing significant public health challenges. However, research in China has largely focused on female populations, with limited data on male HPV prevalence and genotype distribution. This study aims to evaluate HPV prevalence rates and analyze the distribution of various HPV genotypes among male participants in Shantou, China. Methods: A retrospective study was conducted, analyzing data from 2399 male patients who underwent HPV screening at Shantou Central Hospital between 2019 and 2023. PCR-reverse dot blot hybridization techniques were employed to identify and characterize 21 distinct HPV genotypes in the study population. Results: The overall HPV positivity rate was 44.27% (1062/2399; 95% CI: 42.28%-46.26%), with high-risk HPV (HR-HPV) accounting for 24.47% (587/2399; 95% CI: 22.75%-26.19%) and low-risk HPV (LR-HPV) for 32.06% (769/2399; 95% CI: 30.19%-33.92%). Single infections were more common (27.64%), with HPV16 (5.21%), HPV52 (5.13%), and HPV51 (4.54%) being the most prevalent HR-HPV genotypes. HPV6 (18.51%) and HPV11 (10.38%) were the most common LR-HPV types. Coinfections involving HPV6, HPV11, and HPV16 were frequently observed. The nine-valent HPV vaccine (9vHPV) covered 65.25% of LR-HPV and 42.00% of HR-HPV types in this study. Conclusion: Our findings underscore the high burden of HPV infections among males in Shantou, highlighting the need for targeted prevention strategies, including vaccination programs, to reduce the incidence of HPV-related diseases in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.